A first-in-human clinical study to assess safety and tolerability of genetically modified T-cells in ROR1 positive tumors
Phase 1
Recruiting
- Conditions
- Mantle cell lymphomaOvarian cancerAdrenocortical carcinomaBreast cancerChronic lymphocytic leukemia
- Registration Number
- 2024-512019-36-00
- Lead Sponsor
- Universitaetsklinikum Wuerzburg AöR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing, recruiting
- Sex
- Not specified
- Target Recruitment
- 46
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Universitaetsklinikum Wuerzburg AöR
🇩🇪Wuerzburg, Germany
Universitaetsklinikum Wuerzburg AöR🇩🇪Wuerzburg, GermanyHermann EinseleSite contact+4993120140001einsele_h@ukw.de